Comparing Naoxintong and Clopidogrel for Heart Health
Author Information
Author(s): Chen Hui, Yu Guangwei, Sun Hong, Wu Xiaoying, Wang Huan
Primary Institution: Fujian Provincial Cardiovascular Disease Institute
Hypothesis
Does adjunctive Buchang Naoxintong enhance the effects of clopidogrel in volunteers with the CYP2C19*2 gene mutation and specific health conditions?
Conclusion
Adjunctive Buchang Naoxintong to clopidogrel can enhance the antiplatelet effect in volunteers with the CYP2C19*2 gene mutation.
Supporting Evidence
- Maximal platelet aggregation significantly decreased after drug therapy compared to baseline.
- Percent inhibitions of platelet aggregation were lowest in the CYP2C19*2/*2 genotype after clopidogrel administration.
- Changes in platelet activation markers were similar to changes in platelet aggregation.
Takeaway
This study looked at how a traditional Chinese medicine called Naoxintong can help people who have a specific gene mutation and are taking a heart medication called clopidogrel.
Methodology
Eighteen male volunteers with specific genetic and health conditions were treated with clopidogrel and Naoxintong, and their platelet aggregation was measured.
Potential Biases
Potential bias due to the small sample size and the specific selection criteria for volunteers.
Limitations
The study population is small and consists of volunteers rather than patients.
Participant Demographics
Eighteen male volunteers aged between 25 and 55 with the CYP2C19*2 gene mutation.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website